Status:
COMPLETED
An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.
Lead Sponsor:
Henry Ford Health System
Collaborating Sponsors:
Microdermis Corporation
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
13-120 years
Phase:
NA
Brief Summary
The purpose of this study is to compare the efficacy of Provodine™ topical cream to 10% benzoyl peroxide topical body wash for the treatment of early stage hidradenitis suppurativa.
Detailed Description
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disease of the skin. It typically manifests as nodules and abscesses that ultimately can progress to form deep sinus tracts, fistulas...
Eligibility Criteria
Inclusion
- For inclusion, the subject must:
- Be at least 13 years old.
- Be otherwise healthy.
- Have a diagnosis of HS.
- Patients must have Hurley stage I or Stage II HS
- Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form.
- Agree to follow and undergo all study-related procedures.
- If applicable, minors must have permission of legal guardian for participation in the study.
Exclusion
- Subjects who meet the following criteria will be excluded:
- Patients with HS Hurley stage III will be excluded from participation in the study
- Patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of the topical medications.
- Concomitant use of systemic or other topical treatments for HS not involved in current study. For cohort I, no washout period for systemic and/or topical medications will be required. For Cohort II, there will be a 14 day minimum washout period for systemic and topical treatments for HS.
- Any reason the investigator feels the patient should not participate in the study.
- If a patient misses ≥ 2 consecutive study visits, the patient will be excluded from further participation in this trial.
- History of allergy to iodine or benzoyl peroxide.
Key Trial Info
Start Date :
January 5 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 21 2015
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01818167
Start Date
January 5 2013
End Date
January 21 2015
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Medical Center Department of Dermatology
Detroit, Michigan, United States, 48202